The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: New recurrence-free survival results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial at three-year median follow-up.
 
Alexander M. Eggermont
Stock and Other Ownership Interests - RiverD; Skyline Diagnostics; Theranovir
Honoraria - BIOCAD; BIOINVENT; Bristol-Myers Squibb; CatalYm; Ellipses Pharma; GlaxoSmithKline; iOMEDICO; ISA Pharmaceuticals; MSD; NEKTAR; Novartis; Pfizer; Sanofi; Sellas Life Sciences; Skyline Diagnostics
Consulting or Advisory Role - BIOINVENT; Bristol-Myers Squibb; CatalYm; Ellipses Pharma; GlaxoSmithKline; Incyte; iOMEDICO; ISA Pharmaceuticals; MSD; NEKTAR; Novartis; Pfizer; Sanofi; Sellas Life Sciences; Skyline Diagnostics
Speakers' Bureau - MSD
Expert Testimony - Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Christian U. Blank
Stock and Other Ownership Interests - Forty Seven; Neon Therapeutics; Uniti Cars
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); GenMab (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst); Third Rock Ventures
Research Funding - Bristol-Myers Squibb (Inst); NanoString Technologies (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Mario Mandalà
Speakers' Bureau - Bristol-Myers Squibb; MSD
 
Georgina V. Long
Honoraria - Bristol-Myers Squibb; Merck; Pierre Fabre
Consulting or Advisory Role - Aduro Biotech; Amgen; Array BioPharma; Bristol-Myers Squibb; GlaxoSmithKline UK Ltd.; Hexal; MERCK; Novartis; OncoSec; Pierre Fabre; Roche
 
Victoria Atkinson
Honoraria - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche
Speakers' Bureau - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Roche/Genentech
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme; OncoSec; Pierre Fabre
 
Stéphane Dalle
Employment - Sanofi (I)
Stock and Other Ownership Interests - Sanofi (I)
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pierre Fabre
 
Andrew Mark Haydon
Honoraria - Merck; Novartis
Consulting or Advisory Role - Novartis; Pierre Fabre
Speakers' Bureau - Merck; Novartis
 
Andrey Meshcheryakov
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly; Merck
Expert Testimony - AstraZeneca; Bristol-Myers Squibb; Lilly; Merck; Sanofi
Travel, Accommodations, Expenses - BioCad; Lilly; Merck Serono; MSD; Sanofi; SERVIER
 
Muhammad Khattak
Speakers' Bureau - MSD
Travel, Accommodations, Expenses - MSD
 
Matteo S. Carlino
Honoraria - Bristol-Myers Squibb; MSD; Novartis
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; IDEAYA Biosciences; MSD; Novartis; Pierre Fabre; Roche
 
Shahneen Kaur Sandhu
Honoraria - Amgen; Bristol-Myers Squibb; Merck; Merck Serono
Consulting or Advisory Role - Amgen
Speakers' Bureau - Bristol-Myers Squibb; Merck; Roche/Genentech
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
Susana Puig
Consulting or Advisory Role - Almirall; Isdin; Meo Pharma; Sanofi
Speakers' Bureau - Bioderma; Bristol-Myers Squibb; La Roche-Posay; Pierre Fabre; Roche; Sanofi
Research Funding - Almirall (Inst); AML Hub (Inst); Castle Biosciences (Inst); Leo Pharma (Inst); Melagenics (Inst)
Travel, Accommodations, Expenses - Almirall; Bioderma; Sanofi
 
Paolo Antonio Ascierto
Stock and Other Ownership Interests - PrimeVax
Consulting or Advisory Role - 4SC; Alkermes; Amgen; Array BioPharma; AstraZeneca; Bristol-Myers Squibb; Genmab; Idera; Immunocore; Incyte; Italfarmaco; MedImmune; Merck Serono; Merck Sharp & Dohme; Nektar; Newlink Genetics; Novartis; Pierre Fabre; Roche/Genentech; Sandoz; Sanofi; Sun Pharma; Syndax; Ultimovacs
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Alexander Christopher Jonathan Van Akkooi
Consulting or Advisory Role - 4SC (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); MSD Oncology (Inst); Novartis (Inst); Sanofi (Inst)
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Novartis
 
Clemens Krepler
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Nageatte Ibrahim
Employment - Merck
Stock and Other Ownership Interests - GlaxoSmithKline; Merck
 
Sandrine Marreaud
No Relationships to Disclose
 
Michal Kicinski
No Relationships to Disclose
 
Stefan Suciu
No Relationships to Disclose
 
Caroline Robert
Consulting or Advisory Role - Amgen; Biothera; Bristol-Myers Squibb; CureVac; Merck; MSD; Novartis; Pierre Fabre; Roche; Sanofi